Fig. 1From: Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in miceEscitalopram treatment of APPSWE/PS1ΔE9 (APP/PS1) mice. a, b Autoradiograms showing the binding of the 3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile radioligand to brain sections from APP/PS1 mice treated with escitalopram (3.83 ± 0.2 mg/kg/day) or vehicle for 1 month, with non-specific binding (NSB) shown to the right (a). Graphic presentation showing the serotonin transporter occupancy (as a percentage) in neocortex and hippocampus (b). c–e Escitalopram intake (c), body weight (d) and water intake (e) in the experimental mice treated with escitalopram from 3 to 9 months of age. The concentration of escitalopram in the drinking water was adjusted to reach 5 mg/kg/day (4.79 ± 0.27 mg/kg/day). Each coloured line represents one mouse, and the dashed line is the average for all the miceBack to article page